Imunon (NasdaqCM:IMNN) - Share price, News & Analysis

IMNN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

IMNN Stock Overview

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies.

Rewards

Revenue is forecast to grow 83.52% per year

Risk Analysis

Makes less than USD$1m in revenue ($500K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($12M)

Imunon Competitors

Qualigen Therapeutics

NasdaqCM:QLGN

US$11.3m

Yubo International Biotech

OTCPK:YBGJ

US$8.6m

Mymetics

OTCPK:MYMX

US$11.5m

TC Biopharm (Holdings)

NasdaqCM:TCBP

US$10.2m

Price History & Performance

Summary of all time highs, changes and price drops for Imunon
Historical stock prices
Current Share Price	US$1.66
52 Week High	US$15.75
52 Week Low	US$1.54
Beta	2.26
1 Month Change	-26.87%
3 Month Change	-11.70%
1 Year Change	-88.49%
3 Year Change	-92.52%
5 Year Change	-98.17%
Change since IPO	-99.99%

Recent News & Updates

Sep 19

Celsion changes name to Imunon (IMNN)

Celsion (NASDAQ:CLSN) announced Monday its decision to change company's name to Imunon. The new name of clinical-stage drug development company is claimed to outline the "evolution of its business and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases." Stock will begin trading under the new ticker symbol "IMNN", effective Sept 21, 2022. "With a strong balance sheet supporting current operations into 2025, we are well positioned to build a differentiated company to deliver on the promise of our gene-based therapies," commented Dr. Corinne Le Goff, president and CEO of Imunon. Earlier: Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Celsion (NASDAQ:CLSN) said on Thursday that additional data from its completed proof-of-concept mouse challenge study confirmed that its DNA-based placcine vaccine can produce robust levels of ImmunoglobulinG, neutralizing antibodies, and T-cell responses. The additional data from its now completed mouse challenge study showed the ability of the company’s Placcine vaccine to protect a SARS-CoV-2 mouse model in a live viral challenge. In the study, mice were vaccinated with a Placcine vaccine expressing the SARS-CoV-2 spike antigen from the D614G variant or the Delta variant, or a combination vaccine expressing both the D614G and Delta spike variants. The vaccination was administered by intramuscular injection on Day 0 and Day 14, followed by challenge with live SARS-CoV-2 virus on Day 42, the company said. The company expects additional data from this program in non-human primates in the second half of this year.

Aug 12

Celsion Q2 2022 Earnings Preview

Celsion (NASDAQ:CLSN) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$0.91 (-1416.7% Y/Y) and the consensus Revenue Estimate is $0.11M (-15.4% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revision and 1 downward. Revenue estimates have seen 0 upward revision and 0 downward.

Shareholder Returns

	IMNN	US Biotechs	US Market
7D	-15.3%	-3.3%	-5.8%
1Y	-88.5%	-27.4%	-22.1%

Return vs Industry: IMNN underperformed the US Biotechs industry which returned -30.6% over the past year.

Return vs Market: IMNN underperformed the US Market which returned -23.7% over the past year.

Price Volatility

Is IMNN's price volatile compared to industry and market?
IMNN volatility
IMNN Average Weekly Movement	9.0%
Biotechs Industry Average Movement	11.0%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	2.8%

Stable Share Price: IMNN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: IMNN's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1982	29	Corinne Goff	https://www.imunon.com

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies.

Imunon Fundamentals Summary

How do Imunon's earnings and revenue compare to its market cap?
IMNN fundamental statistics
Market Cap	US$11.78m
Earnings (TTM)	-US$26.15m
Revenue (TTM)	US$500.00k

23.6x

P/S Ratio

-0.5x

P/E Ratio

Is IMNN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMNN income statement (TTM)
Revenue	US$500.00k
Cost of Revenue	US$11.78m
Gross Profit	-US$11.28m
Other Expenses	US$14.87m
Earnings	-US$26.15m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-3.68
Gross Margin	-2,255.20%
Net Profit Margin	-5,229.82%
Debt/Equity Ratio	12.6%

How did IMNN perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is IMNN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMNN?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for IMNN. This is calculated by dividing IMNN's market cap by their current preferred multiple.
What is IMNN's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$11.78m

IMNN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does IMNN's PS Ratio compare to its peers?

IMNN PS Ratio vs Peers

The above table shows the PS ratio for IMNN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	9.8x
QLGN Qualigen Therapeutics	2.4x	19.7%	US$11.3m
YBGJ Yubo International Biotech	18.9x	n/a	US$8.6m
MYMX Mymetics	13x	n/a	US$11.5m
TCBP TC Biopharm (Holdings)	4.8x	n/a	US$10.2m
IMNN Imunon	23.6x	83.5%	US$11.8m

Price-To-Sales vs Peers: IMNN is expensive based on its Price-To-Sales Ratio (23.6x) compared to the peer average (9.8x).

Price to Earnings Ratio vs Industry

How does IMNN's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: IMNN is expensive based on its Price-To-Sales Ratio (23.6x) compared to the US Biotechs industry average (12.3x)

Price to Sales Ratio vs Fair Ratio

What is IMNN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMNN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	23.6x
Fair PS Ratio	0x

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IMNN's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of IMNN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IMNN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IMNN's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Imunon forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

24.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMNN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMNN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMNN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMNN's revenue (83.5% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: IMNN's revenue (83.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IMNN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Imunon performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-4.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IMNN is currently unprofitable.

Growing Profit Margin: IMNN is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: IMNN is unprofitable, and losses have increased over the past 5 years at a rate of 4.8% per year.

Accelerating Growth: Unable to compare IMNN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMNN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: IMNN has a negative Return on Equity (-55.59%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Imunon's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IMNN's short term assets ($44.9M) exceed its short term liabilities ($6.9M).

Long Term Liabilities: IMNN's short term assets ($44.9M) exceed its long term liabilities ($11.4M).

Debt to Equity History and Analysis

Debt Level: IMNN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if IMNN's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMNN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMNN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 0.8% each year.

Discover healthy companies

Dividend

What is Imunon current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Imunon Dividend Yield vs Market

How does Imunon dividend yield compare to the market?
Segment	Dividend Yield
Company (Imunon)	n/a
Market Bottom 25% (US)	1.7%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.8%
Analyst forecast in 3 Years (Imunon)	n/a

Notable Dividend: Unable to evaluate IMNN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMNN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMNN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMNN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IMNN has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.3yrs

Average management tenure

CEO

Corinne Goff

0.17yr

Tenure

Dr. Corinne Le Goff, Pharm. D. & M. B. A., serves as Independent Director at Euroapi S. A. She serves as Independent Director of the Board for Acticor Biotech SAS since 2022 and is CEO, President & Directo...

Leadership Team

Experienced Management: IMNN's management team is seasoned and experienced (8.3 years average tenure).

Board Members

Experienced Board: IMNN's board of directors are seasoned and experienced ( 11.7 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

NasdaqCM:IMNN Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
12 Apr 22	BuyUS$14,129	Michael Tardugno	Individual	4,000	US$3.53
08 Apr 22	BuyUS$20,250	Frederick Fritz	Individual	5,000	US$4.05
02 Mar 22	BuyUS$9,372	Frederick Fritz	Individual	2,000	US$4.69
07 Oct 21	BuyUS$17,600	Frederick Fritz	Individual	1,333.33	US$13.20

Ownership Breakdown

What is the ownership structure of IMNN?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	12,698	0.2%
Individual Insiders	94,250	1.3%
Institutions	1,178,914	16.6%
General Public	5,812,879	81.9%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23%.

Top Shareholders

Top 25 shareholders own 18.06% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
3.9%	Murchinson Ltd. , Asset Management Arm	276,644	$459.2k	0%	0.1%
3.31%	The Vanguard Group, Inc.	234,953	$390.0k	0%	no data
2.58%	FiveT Capital AG	183,333	$304.3k	0%	5.07%
1.61%	Two Sigma Advisers, LP	114,304	$189.7k	187.65%	no data
1.03%	Heights Capital Management, Inc.	73,333	$121.7k	0%	0.01%
0.95%	BlackRock, Inc.	67,730	$112.4k	-9.59%	no data
0.75%	Corinne Le Goff	53,000	$88.0k	0%	no data
0.74%	Renaissance Technologies LLC	52,311	$86.8k	96.99%	no data
0.74%	Susquehanna International Group, LLP, Asset Management Arm	52,274	$86.8k	0%	no data
0.71%	Geode Capital Management, LLC	50,457	$83.8k	0%	no data
0.28%	Two Sigma Investments, LP	19,883	$33.0k	-44.02%	no data
0.23%	Michael Tardugno	16,513	$27.4k	0%	no data
0.2%	State Street Global Advisors, Inc.	14,303	$23.7k	0%	no data
0.19%	Tower Research Capital LLC	13,292	$22.1k	159.2%	no data
0.18%	Ionic Ventures, LLC	12,698	$21.1k	0%	no data
0.17%	Frederick Fritz	11,766	$19.5k	0%	no data
0.16%	Citigroup Inc.,Banking and Securities Investments	11,194	$18.6k	0%	no data
0.07%	Investors Asset Management Of Georgia Inc.	5,000	$8.3k	0%	no data
0.051%	Jeffrey Church	3,617	$6.0k	0%	no data
0.048%	Group One Trading LP, Asset Management Arm	3,429	$5.7k	-3.52%	no data
0.048%	Nicholas Borys	3,427	$5.7k	0%	no data
0.04%	Khursheed Anwer	2,855	$4.7k	0%	no data
0.031%	Morgan Stanley, Investment Banking and Brokerage Investments	2,232	$3.7k	-15.07%	no data
0.027%	Blackstone Inc.	1,913	$3.2k	272.9%	no data
0.024%	Robert Hooper	1,712	$2.8k	0%	no data

Ticker	Exchange	Primary Security	Security Type	Country	Currency	Listed on
IMNN	NasdaqCM (Nasdaq Capital Market)	Yes	Common Stock	US	USD	Mar 1985
CBO	DB (Deutsche Boerse AG)	Yes	Common Stock	DE	EUR	Mar 1985
0HUZ	LSE (London Stock Exchange)	Yes	Common Stock	GB	USD	Mar 1985

Data	Last Updated (UTC time)
Company Analysis	2022/09/27 00:00
End of Day Share Price	2022/09/27 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31